# Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/real-world-evidence-considerations-regarding-non-interventional-studies-for-drug-and-biological-products/48325e39-b445-4a53-8cc0-7483dcf3e352

> FDA guidance document: Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products. Issue date: March 21, 2024. Get complete insights and analysis.

---

## Details

- Title: Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2024-03-21
- Comment Close Date: 2024-06-18
- Last Changed: 2024-04-08
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2023-D-5470">FDA-2023-D-5470</a>

## Related Documents

- [Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products: Draft Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/use-of-bayesian-methodology-in-clinical-trials-of-drug-and-biological-products-draft-guidance-for-industry/8e9c345e-0994-47b3-8d6c-054f04ed937e)
- [Regulatory Considerations for Prescription Drug Use-Related Software](https://www.globalkeysolutions.net/guidances/guidance-document/regulatory-considerations-for-prescription-drug-use-related-software/91768cc9-a953-4b59-9da8-4726750c15e7)
- [Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products](https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-the-design-and-conduct-of-externally-controlled-trials-for-drug-and-biological-products/9dafe0c9-19d4-48c0-a1ca-6b2a04a813ed)